Phase II study of a protracted irinoteca
✍
Gianni Bisogno; Riccardo Riccardi; Antonio Ruggiero; Giampaolo Arcamone; Arcange
📂
Article
📅
2006
🏛
John Wiley and Sons
🌐
English
⚖ 85 KB
👁 2 views
## Abstract ## BACKGROUND Irinotecan (CPT‐11) is a novel antineoplastic agent that takes effect by inhibiting topoisomerase I. The Italian Soft Tissue Sarcoma (STS) Committee performed a multiinstitutional Phase II study to evaluate its effect on STS. ## METHODS Over a 2‐year period between 2002